SCHEMBL30503102

SCHEMBL30503102

c1ccc(N2CCc3c(-c4cncnc4)nc(N4CCOCC4)nc32)cc1

nearest known ligand 0.83

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 20/20 0.83
PIK3R1 P27986 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25405149 1.00 PIK3CA (0.83) PIK3CAPIK3R1
SCHEMBL2376229 0.91 PIK3CA (1.00) PIK3CAPIK3R1
SCHEMBL30503111 0.90 PIK3CA (0.88) PIK3CAPIK3R1
SCHEMBL25402630 0.90 PIK3CA (0.88) PIK3CAPIK3R1
SCHEMBL30503095 0.89 PIK3CA (0.89) PIK3CAPIK3R1
SCHEMBL25405259 0.89 PIK3CA (0.89) PIK3CAPIK3R1
SCHEMBL2376424 0.88 PIK3CA (1.00) PIK3CAPIK3R1
SCHEMBL2376772 0.86 PIK3CA (0.89) PIK3CAPIK3R1
SCHEMBL31230003 0.86 PIK3CA (0.74) PIK3CAPIK3R1
SCHEMBL25618608 0.86 PIK3CA (0.74) PIK3CAPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. 2025-05-08 US disclosed
US-20230271965-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE YUMANITY THERAPEUTICS, INC. 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271965-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE NLN, GRIN2C, BCHE PIK3CA 4620/4885PIK3R1 4349/4885
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE TARDBP, TDP2, PSEN2 PIK3CA 4005/4885PIK3R1 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.